Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LEGN with free AI briefings, catalyst countdowns, and dilution alerts.

LEGN · Legend Biotech Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$852.5M Cash on Hand
66.4mo Cash Runway
Follow LEGN by email Get an email when LEGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LEGN, unsubscribe in one click. Privacy

📣 What LEGN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
LCAR- F33S cells intravenous infusion Relapsed/Refractory Multiple Myeloma(MM) N/A · NCT07100067 Recruiting
LCAR-B38M CAR-T Cell Refractory or Relapsed Multiple Myeloma Phase 1/2 · NCT03090659 Unknown
LCAR-BCX cells product Relapsed/Refractory Multiple Myeloma Phase 1 · NCT04601935 Unknown
CAR-T Re-treatment Multiple Myeloma Phase 1 · NCT03672253 Unknown
LCAR-C18S cells Solid Tumors, Adult Phase 1 · NCT04467853 Terminated
Autologous GCC-targeting CAR T-cells LCAR-G08 Advanced Gastrointestinal Tumors Phase 1 · NCT06197178 Terminated
LCAR-HL30 cells Hodgkin's Lymphoma Phase 1 · NCT06494371 Recruiting
LCAR-M23 cells Epithelial Ovarian Cancer Phase 1 · NCT04562298 Terminated
LUCAR-20SP cells Relapsed B-cell Non-Hodgkin Lymphoma Phase 1 · NCT06313957 Recruiting
LUCAR-B68 cells product Relapsed/Refractory Multiple Myeloma Phase 1 · NCT05498545 Terminated
LUCAR-G39D cells product B-Cell Non-Hodgkin Lymphoma-Recurrent Phase 1 · NCT06395870 Recruiting
LUCAR-G39P cells product Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Phase 1 · NCT06295549 Terminated
LUCAR-G79 T cells Relapsed/Refractory Autoimmune Diseases Phase 1 · NCT07049081 Terminated
LUCAR-G79D T cells Systemic Lupus Erythematosus (SLE) Phase 1 · NCT07331272 Recruiting
LVIVO-TaVec122 product Relapsed/Refractory B-cell Malignancies Phase 1 · NCT07628582 Not yet recruiting
LCAR-BCDR cells product Relapsed/Refractory Multiple Myeloma Phase 1 · NCT05376345 Completed

Also used in these trials (approved or third-party drugs, not LEGN's own candidates): Cyclophosphamide, Ciltacabtagene Autoleucel.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LEGN holds $852.5M in cash and short-term investments and burns about $38.5M/quarter from operations, an estimated runway of 66.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LEGN files for a raise →

👥 Who Owns LEGN

Insiders 0.5% Institutions (324 holders) 51.6% Public and other holders 47.9%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 48,164,808 13.02% 2026-09-30
Ingrid Zhang
Chief Executive Officer
Insider 1,131,860 0.31% 2026-09-15
Ying Huang
Chief Executive Officer, Director
Insider 238,490 0.06% 2026-06-30
Darren Xiaohui Ji
Director
Insider 92,103 0.02% 2026-09-24
Peter Salovey
Director
Insider 75,096 0.02% 2026-11-12
Patrick John Casey
Director
Insider 69,590 0.02% 2026-09-24
Li Mao
Director
Insider 65,316 0.02% 2026-09-24
Tomas J. Heyman
Director
Insider 53,720 0.01% 2026-09-24
Corazon (Corsee) D. Sanders
Director
Insider 52,731 0.01% 2026-09-29
Alan Bash
Interim CEO
Insider 35,142 0.01% 2026-08-14
Gareth Kung
Director
Insider 31,486 0.01% 2026-03-18
Carlos E Santos
Chief Financial Officer
Insider 14,246 0.00% 2026-09-21

Share count 369,886,369 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LEGN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LEGN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.